Among the many central nervous system therapeutic areas associated with modulatory activity of the GABAA ion channel, GABAA α5-subtype negative allosteric modulators (NAMs) have been a focus of interest for the treatment of cognitive disorders. Join this webinar to learn how scientists identified a novel, orally active GABAA α5-selective NAM that improved hippocampal memory function without the anxiogenic-like or pro-convulsant effects associated with non-selective GABAA NAMs.
Through a case study of ONO-8590580, you’ll discover strategies to take a metabolically unstable hit compound through lead optimization, improving functional selectivity, absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK) and brain receptor occupancy along the way.
Mark Chambers, PhD
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.